Overview

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether a medication, Clonidine can reduce the number of days a baby spends in the hospital and the number of days of medical treatment of withdrawal from Neonatal Abstinence Syndrome (NAS) as compared to Morphine Sulfate (used in routine care) .
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The Cooper Health System
Treatments:
Clonidine
Morphine
Criteria
Inclusion Criteria:

- Born at Cooper University Hospital

- Greater than or equal to 35 weeks gestation age

- Admitted to the NICU or Transitional nursery

- Mothers admitted to using illicit substances or prescription medications (which can
result in withdrawal symptoms) while pregnant and/or had a positive urine drug screen
during pregnancy.

- Babies being started on medication to control withdrawal symptoms of NAS.

- No congenital anomalies or neurologic condition (i.e. hypoxic-ischemic encephalopathy,
seizures, meningitis etc.)

Exclusion Criteria:

- Premature infants <35 week gestational age

- Infants with major congenital abnormalities

- Blood pressure instability

- Major medical conditions